CARE reaffirms rating of Themis Medicare’s bank facilities

16 Apr 2013 Evaluate

Credit rating agency, CARE has reaffirmed D rating to Themis Medicare’s long term bank facilities worth Rs 13.10 crore. The rating agency has also reaffirmed D rating to the company’s short term bank facilities.

The company has received the said rating reaffirmation due to delay in repayment of term loans and interest servicing on its debt obligations owing to liquidity constraints.

Themis Medicare is engaged in supplying its research formulations to well known Pharmaceutical companies in India namely Alkem Lab, Fulford, Intas Pharmaceuticals, IPCA Lab., Cadila Healthcare, Aristo Pharma, Mankind Pharma, Shreya Lifesciences, Nicholas Piramal, Unichem Lab, etc.

Themis Medicare Share Price

100.10 -1.60 (-1.57%)
29-Dec-2025 14:26 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1714.40
Dr. Reddys Lab 1265.90
Cipla 1496.80
Zydus Lifesciences 905.95
Lupin 2085.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×